Mochida Pharmaceutical Co., Ltd.

Kiyoshi Mizuguchi

Tsuyoshi Harada

Kazuo Kato

Hiroyuki Kawano

Ichiro Yamamoto

Hidenori Mochizuki

Masayuki Ichioka

Shuhei Ohnishi

Hideo Kanehiro

Atsushi Osada

Tsutomu Satoh

Yutaka Kato

Kimihiro Murakami

Nobuo Ohzawa

Kazuyuki Matsuura

Kazutoshi Yanagibashi

Yasuhiro Nakai

Ayako Suzuki

The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.

Compositions and methods for treating non-alcoholic steatohepatitis

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (NASH).

The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH).

This invention provides novel benzimidazole derivatives represented by the formula (I); a process for producing the same; a drug containing at least one of such compounds as its active ingredient, in particular, a drug for preventing and/or treating diseases exhibiting eosinophilia, bronchial asthma and allergic diseases; and an enhancer for IFN-&ggr; production, and in particular, an antitumor agent or an antiviral agent based on the action of enhancing the IFN-&ggr; production which exhibits excellent oral bioavailability.

Benzimidazole derivatives

Imidazoquinoline derivatives

Tricyclic compound having anti-allergic activities

The present invention relates to novel 5-(.omega.-substituted amino-alkanoyl amino)pyrimidine derivatives, processes for producing the derivatives, and pharmaceutical compositions containing said derivatives. The compounds in the present invention have potent effects of inhibiting ACAT activity and lowering serum cholesterol. The compounds of the present invention are extremely useful for the treatment and/or prevention of arteriosclerosis or hyperlipidemia.

Pyrimidine derivatives

Growing community of inventors

Tokyo, Japan

Kiyoshi Mizuguchi